ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116

References

• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7:505 - 16; http://dx.doi.org/10.1038/nrm1962; PMID: 16829981
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7:493 - 507; http://dx.doi.org/10.1038/nrclinonc.2010.97; PMID: 20551942
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463 - 75; http://dx.doi.org/10.1038/nrc2656; PMID: 19536107
   PubMed Web of Science ®Google Scholar
• Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol 2011; 8:369 - 83; http://dx.doi.org/10.1038/nrgastro.2011.81; PMID: 21647199
   PubMed Web of Science ®Google Scholar
• Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 2011; 11:793 - 800; http://dx.doi.org/10.4161/cbt.11.9.15045; PMID: 21307659
   PubMed Web of Science ®Google Scholar
• Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart MJ. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol 2013; 24:273 - 82; http://dx.doi.org/10.1093/annonc/mds328; PMID: 22910839
   PubMed Web of Science ®Google Scholar
• Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 2010; 21:944 - 50; http://dx.doi.org/10.1016/j.semcdb.2010.08.007; PMID: 20816829
   PubMed Web of Science ®Google Scholar
• Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res 2009; 69:2191 - 4; http://dx.doi.org/10.1158/0008-5472.CAN-08-1056; PMID: 19276389
   PubMed Web of Science ®Google Scholar
• Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010; 16:1373 - 83; http://dx.doi.org/10.1158/1078-0432.CCR-09-1218; PMID: 20179223
   PubMed Web of Science ®Google Scholar
• Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 1992; 7:1273 - 8; PMID: 1377811
   PubMed Web of Science ®Google Scholar
• Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res 2013; 73:5183 - 94; http://dx.doi.org/10.1158/0008-5472.CAN-13-0099; PMID: 23780344
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011; 29:3783 - 90; http://dx.doi.org/10.1200/JCO.2011.34.8888; PMID: 21900113
   PubMed Web of Science ®Google Scholar
• van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm 2010; 25:375 - 85; http://dx.doi.org/10.1089/cbr.2010.0812; PMID: 20707716
   PubMed Web of Science ®Google Scholar
• Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48:1313 - 9; http://dx.doi.org/10.2967/jnumed.107.041301; PMID: 17631557
   PubMed Web of Science ®Google Scholar
• Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de Jong JR, de Vries EG, Lub-de Hooge MN. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009; 50:974 - 81; http://dx.doi.org/10.2967/jnumed.108.060392; PMID: 19443585
   PubMed Web of Science ®Google Scholar
• Oosting SF, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Brouwers AH, Glaudemans AW, De Jong IJ, Scherer SJ, Gietema JA, De Vries EG. 89Zr-bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification. EORTC-NCI-AACR meeting abstracts 2010, #221
   Google Scholar
• Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87:586 - 92; http://dx.doi.org/10.1038/clpt.2010.12; PMID: 20357763
   PubMed Web of Science ®Google Scholar
• Sharp TL, Glaus C, Fettig N, Hewig A, Ogbagabriel S, Freeman D, Beaupre D, Hwang D, Welch MJ. Pharmacological evaluation of 64Cu-DOTA-AMG888 (U3-1287) in control and tumor bearing mice using biodistribution and microPET imaging. Proc World Molecular Imaging Congress 2011; abstract #T206.
   Google Scholar
• Malm M, Kronqvist N, Lindberg H, Gudmundsdotter L, Bass T, Frejd FY, Höidén-Guthenberg I, Varasteh Z, Orlova A, Tolmachev V, et al. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One 2013; 8:e62791; http://dx.doi.org/10.1371/journal.pone.0062791; PMID: 23675426
   PubMed Web of Science ®Google Scholar
• Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, Lambin P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009; 50:123 - 31; http://dx.doi.org/10.2967/jnumed.108.054312; PMID: 19091906
   PubMed Web of Science ®Google Scholar
• Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009; 50:1116 - 23; http://dx.doi.org/10.2967/jnumed.109.061820; PMID: 19525473
   PubMed Web of Science ®Google Scholar
• Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 2008; 23:158 - 71; http://dx.doi.org/10.1089/cbr.2007.0444; PMID: 18454685
   PubMed Web of Science ®Google Scholar
• Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007; 34:850 - 8; http://dx.doi.org/10.1007/s00259-006-0361-6; PMID: 17262214
   PubMed Web of Science ®Google Scholar
• Misri R, Saatchi K, Ng SS, Kumar U, Häfeli UO. Evaluation of (111)In labeled antibodies for SPECT imaging of mesothelin expressing tumors. Nucl Med Biol 2011; 38:885 - 96; http://dx.doi.org/10.1016/j.nucmedbio.2011.02.013; PMID: 21843785
   PubMed Web of Science ®Google Scholar
• Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res 2013; 19:1126 - 38; http://dx.doi.org/10.1158/1078-0432.CCR-12-0989; PMID: 23209031
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687 - 717; http://dx.doi.org/10.1016/S0140-6736(05)66544-0; PMID: 15894097
   PubMed Web of Science ®Google Scholar
• Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642 - 9; http://dx.doi.org/10.1200/JCO.2007.11.6699; PMID: 18375893
   PubMed Web of Science ®Google Scholar
• Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med 2003; 44:1271 - 81; PMID: 12902418
   PubMed Web of Science ®Google Scholar
• Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 1990; 50:4221 - 6; PMID: 2364380
   PubMed Web of Science ®Google Scholar
• Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003; 2:131 - 7; http://dx.doi.org/10.1162/153535003322556877; PMID: 14649056
   PubMedGoogle Scholar